Reumatologia clinica最新文献

{"title":"Prevalence of latent tuberculosis in patients with rheumatological diseases exposed to biologic drugs and small molecules: A study based on the BIOBADAMEX national registry","authors":"Luis Francisco Valdés Corona ,&nbsp;Ana González Andrade ,&nbsp;Aylin Luna Salazar ,&nbsp;David Vega-Morales ,&nbsp;Jiram Torres-Ruiz ,&nbsp;Iris Jazmín Colunga-Pedraza ,&nbsp;Sandra Sicsik ,&nbsp;Ángel Castillo Ortiz ,&nbsp;Miguel A. Saavedra Salinas ,&nbsp;Guillermo Guaracha-Basáñez ,&nbsp;Dafhne Guadalupe Miranda Hernández ,&nbsp;Fedra Irazoque-Palazuelos ,&nbsp;Sandra Carrillo Vazquez ,&nbsp;Julio Cesar Casasola Vargas ,&nbsp;Omar Eloy Muñoz-Monroy ,&nbsp;Javier Merayo-Chalico ,&nbsp;Estefanía Torres Valdez ,&nbsp;Sergio Duran Barragán ,&nbsp;Erick Adrián Zamora-Theozol ,&nbsp;Daniel Xavier Xibille Friedmann ,&nbsp;Vijaya Rivera Terán","doi":"10.1016/j.reumae.2026.502097","DOIUrl":"10.1016/j.reumae.2026.502097","url":null,"abstract":"<div><h3>Introduction</h3><div>Latent tuberculosis infection (LTBI) represents a challenge in patients with rheumatic diseases treated with immunological drugs, including TNF-α inhibitors, due to the increased risk of progression to active tuberculosis. Identifying the prevalence of LTBI and its associated factors is key to improving screening and prevention of this condition in this vulnerable population.</div></div><div><h3>Objective</h3><div>Primary: To determine the prevalence of LTBI in Mexican patients with rheumatic diseases treated with biologic DMARDs or small molecules.</div><div>Secondary: To identify factors associated with LTBI, considering sociodemographic, clinical, and geographic characteristics.</div></div><div><h3>Materials and Methods</h3><div>This retrospective, descriptive, cross-sectional study was based on 1464 patients included in the BIOBADAMEX database (June 2016–October 2024). All patients with a confirmed diagnosis of rheumatological diseases who had initiated treatment with biologic therapy or small molecules were included, regardless of age or diagnosis. Diagnostic tests included in the registry (tuberculin skin test, tuberculin booster, and quantiferon for tuberculosis) were analyzed to detect latent thrombolytic disease (LTBD). Sociodemographic, clinical, and laboratory variables were analyzed using descriptive statistics and logistic regression models, considering a significance level of 0.05.</div></div><div><h3>Results</h3><div>The prevalence of LTBI was 10.1% among the patients evaluated. A positive association was identified with male sex (OR: 2.64; 95% CI: 1.77, 3.95) and residence in Northern Mexico (OR: 4.74; 95% CI: 1.46, 15.32). BCG vaccination showed a negative association (OR: 0.61; 95% CI: 0.38, 0.98). No significant associations were identified with the type of drug used or relevant comorbidities, except for a negative association with hypercholesterolemia (OR: 0.25; 95% CI: 0.08, 0.81).</div></div><div><h3>Conclusion</h3><div>The study found that the prevalence of latent tuberculosis infection (LTBI) in Mexican patients with rheumatic diseases who are about to begin biologic therapy is consistent with the prevalence of LTBI in the Mexican population. Screening these patients for tuberculosis before initiating biologic therapy allows for the identification of patients with LTBI and enables appropriate management so they can begin biologic therapy of any mechanism of action. This screening should be expanded and applied to 100% of patients starting biologic therapy, paying particular attention to patients with associated risk factors.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 4","pages":"Article 502097"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147679926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge, intentions, and practices of breastfeeding among women with systemic lupus erythematosus: A cross-sectional survey","authors":"María Pía Izaguirre Germain,&nbsp;Susana Villamizar Pérez,&nbsp;Nicole Josianne Paris,&nbsp;Melissa Brenda Serna Góngora,&nbsp;Ariel Brener,&nbsp;Jerson Claros,&nbsp;Emel Gonzalez,&nbsp;Bárbara Cristina Pérez Cepas,&nbsp;Marina Laura Micelli,&nbsp;Gabriel Sequeira,&nbsp;Eduardo Mario Kerzberg","doi":"10.1016/j.reumae.2026.502103","DOIUrl":"10.1016/j.reumae.2026.502103","url":null,"abstract":"<div><h3>Introduction</h3><div>Breastfeeding in systemic lupus erythematosus (SLE) is often influenced by concerns about medication safety, with limited data on patients’ perceptions and decision-making.</div></div><div><h3>Objectives</h3><div>To assess breastfeeding knowledge, intentions, and practices among women with SLE, focusing on disease activity and medication-related perceptions, particularly regarding hydroxychloroquine and prednisone.</div></div><div><h3>Methods</h3><div>A cross-sectional survey was conducted with women diagnosed with SLE. Participants answered questions on demographics, previous pregnancy and breastfeeding experiences, knowledge of breastfeeding with SLE, and perceptions of breastfeeding safety with hydroxychloroquine and prednisone. The survey also assessed their intention to breastfeed in future pregnancies, especially during active disease.</div></div><div><h3>Results</h3><div>The survey was completed by 85 patients, with a mean age of 35 years (SD 9). Of these, 56% reported at least one pregnancy, 53% had breastfed, and 32.9% had a child after being diagnosed with SLE (SLE&amp;Child group). When considering future pregnancies, 88% intended to breastfeed, but 62% prioritized treatment over breastfeeding if SLE was active (<em>p</em> <!-->&lt;<!--> <!-->0.001). After reading patient information leaflets (PILs), 64% considered breastfeeding on prednisone, while only 26% thought it safe with hydroxychloroquine. Breastfeeding knowledge was higher in the SLE&amp;Child group. Initiation rates were 79.3% in the SLE&amp;Child group and 93.2% in controls (<em>p</em> <!-->=<!--> <!-->0.08). The average breastfeeding duration was 14 months in the SLE&amp;Child group and 17 months in controls (log-rank test<!--> <!-->=<!--> <!-->0.5).</div></div><div><h3>Conclusions</h3><div>Most patients with SLE intended to breastfeed, but this intention decreased during active disease. Hydroxychloroquine PILs appeared to discourage breastfeeding despite the drug's safety.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 4","pages":"Article 502103"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147827224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience with nintedanib in interstitial lung disease associated with systemic autoimmune diseases","authors":"Minerva Berrocal Acedo ,&nbsp;Rosalía Martínez Pérez ,&nbsp;Zulema Palacios Hidalgo ,&nbsp;María Luisa Velloso Feijoo","doi":"10.1016/j.reumae.2026.502099","DOIUrl":"10.1016/j.reumae.2026.502099","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 4","pages":"Article 502099"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147679881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lepromatous reaction mimicking a primary systemic vasculitis: Case report and literature review","authors":"Julia Scafati,&nbsp;Claudia Pena,&nbsp;Camila Ramallo,&nbsp;Damián E. Moavro,&nbsp;Mercedes A. García","doi":"10.1016/j.reumae.2026.502106","DOIUrl":"10.1016/j.reumae.2026.502106","url":null,"abstract":"<div><div>Lucio’s phenomenon is a rare necrotizing skin reaction, almost exclusive to diffuse lepromatous leprosy, that can mimic systemic vasculitis and lead to diagnostic and therapeutic errors. We report the case of a 32-year-old woman from Paraguay with prolonged fever, hepatomegaly, and violaceous, painless necrotic skin lesions on her limbs. She was initially treated with corticosteroids for presumed vasculitis without clinical improvement. Physical examination revealed madarosis, lepromas, and altered thermal-pain sensitivity. Skin biopsy showed a perivascular histiocytic infiltrate with acid-fast bacilli, confirming multibacillary lepromatous leprosy. Treatment with rifampicin, dapsone, and clofazimine was initiated, resulting in good clinical evolution. Lucio’s phenomenon is an immune-mediated vasculopathy that may produce false-positive serologies and mimic autoimmune diseases. Histopathological confirmation is essential to avoid unnecessary immunosuppressive therapy. It should be considered in the differential diagnosis of necrotic skin ulcers, especially in patients from endemic regions. Early recognition and specific treatment help prevent severe complications.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 4","pages":"Article 502106"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review and network meta-analysis of interventions for articular involvement in patients with systemic lupus erythematosus","authors":"Pedro Arbey Quevedo Mayorga ,&nbsp;Diana Isabel Muñoz ,&nbsp;Sebastián Giraldo ,&nbsp;Cristhian Camilo Guzmán ,&nbsp;Javier Mauricio Mora ,&nbsp;Jhon Jairo Tipasoca ,&nbsp;Sergio Daniel Montalvo","doi":"10.1016/j.reumae.2026.502105","DOIUrl":"10.1016/j.reumae.2026.502105","url":null,"abstract":"<div><div>Several immunosuppressive therapies beyond corticosteroids have demonstrated efficacy in controlling symptoms and reducing inflammation in lupus-related arthritis. The current standard of care (SOC) remains the combination of antimalarials and low-dose steroids, with the addition of other immunosuppressants in refractory cases. This study aimed to compare the efficacy of available biological and non-biological immunosuppressive therapies in controlling articular activity in patients with systemic lupus erythematosus (SLE). A systematic review and network meta-analysis were conducted following the PRISMA-NMA checklist (PROSPERO registration: CRD42024562392). Randomized controlled trials up to December 2023 evaluating biological and non-biological immunosuppressive treatments in lupus with articular involvement were included. Searches were performed in MEDLINE, EMBASE, LILACS, and SCIELO, including gray literature. Two reviewers independently selected studies, extracted data, and assessed risk of bias (RoB2). A fixed-effects frequentist model was applied using <em>netmeta</em>, estimating relative risks (RR), heterogeneity (I², τ²), and efficacy <em>ranking</em> using <em>P-scores</em>. A total of 1635 records were identified, and five randomized controlled trials met inclusion criteria, comprising 1476 patients, 93.3% of whom were women, with a mean age of 40 years. Evaluated interventions included methotrexate, anifrolumab, and baricitinib, all compared to placebo. Three studies showed low risk of bias, while two presented some concerns in specific domains. The network meta-analysis revealed no significant heterogeneity (Q = 2.44; <em>P</em> = .29) or inconsistency between designs, though global inconsistency was detected by netsplitting analysis. No statistically significant differences in efficacy were observed among the evaluated treatments. In the exploratory <em>ranking</em> analysis, <em>P-scores</em> indicated that methotrexate (<em>P-score</em> = 1.0), baricitinib (<em>P-score</em> = .62), and anifrolumab (<em>P-score</em> = .37) were numerically positioned at the top of the <em>ranking</em>. Nevertheless, these estimates represent probabilistic rather than inferential measures and should therefore be interpreted with caution. Meta-regression did not identify a significant influence of risk of bias on the results (<em>P</em> = .42), although substantial residual heterogeneity was observed (I² = 98.8%), which limits the comparative interpretation of treatment efficacy.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 4","pages":"Article 502105"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gaps between self-perceived sinonasal symptoms, endoscopic findings, and radiographic damage in patients with granulomatosis with polyangiitis","authors":"Emilio Jiménez-Téllez ,&nbsp;Eduardo Martín-Nares ,&nbsp;María Teresa Sánchez-González ,&nbsp;Mahatma I. Guzman-Soto ,&nbsp;Eugenio Salas-Olvera ,&nbsp;Andrea Hinojosa-Azaola","doi":"10.1016/j.reumae.2026.502107","DOIUrl":"10.1016/j.reumae.2026.502107","url":null,"abstract":"<div><h3>Background and objective</h3><div>Sinonasal symptoms occur in up to 80% of patients with granulomatosis with polyangiitis (GPA), affecting quality of life. This study aimed to evaluate the association between self-perceived sinonasal symptoms (SNOT-22 questionnaire), and clinical variables, and to describe discrepancies between self-reported symptoms, ENT findings, and radiographic abnormalities.</div></div><div><h3>Methods</h3><div>A cross-sectional study was conducted at a tertiary center in Mexico City (November 2024–July 2025). Patients with GPA and a paranasal sinus CT scan within two years were included. Data collection comprised demographic, clinical, laboratory, and treatment variables. Assessments included disease activity (BVAS/GPA), cumulative damage (VDI), patient and physician global assessments (PhGA and PtGA), and PROMs (SNOT-22, AAV-PRO). All patients underwent ENT examination with nasal endoscopy.</div></div><div><h3>Results</h3><div>Fifty patients were included, 64% women, median age 49.5 years, and disease duration 88.5 months. Most were in remission (median BVAS/GPA 0). The median VDI was 3, PtGA 10.7<!--> <!-->mm, and PhGA 1.8<!--> <!-->mm. The median SNOT-22 score was 30.5. Common ENT findings were rhinorrhea (64%), hypertrophic turbinates or hyperemic mucosa (36%), nasal crusts (34%), and septal perforation (20%). CT abnormalities included chronic sinusitis (46%) and sinus destruction (32%). Self-reported symptoms showed moderate-to-strong correlations with AAV-PRO domains and global assessments, but no associations with disease activity, damage, or treatment. Discrepancies were observed between SNOT-22 items and ENT or CT findings.</div></div><div><h3>Conclusions</h3><div>Self-reported sinonasal symptoms correlated with PROMs, whereas associations with disease activity or damage were not evident in this cohort. Discrepancies highlight the need for GPA-specific studies integrating PROMs, standardized ENT assessments, and imaging.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 4","pages":"Article 502107"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147827223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of rheumatoid arthritis-associated interstitial lung disease: What is new since the 2022 SER-SEPAR recommendations?","authors":"Javier Narváez ,&nbsp;Petra Díaz del Campo Fontecha ,&nbsp;M. Asunción Nieto ,&nbsp;Virginia Villaverde García ,&nbsp;Gloria Candelas Rodríguez ,&nbsp;Alejandro Balsa","doi":"10.1016/j.reumae.2026.502104","DOIUrl":"10.1016/j.reumae.2026.502104","url":null,"abstract":"<div><h3>Objective</h3><div>In 2020, the Spanish Society of Rheumatology (SER) and the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) published joint recommendations on the management of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Since then, new evidence has emerged supporting an update focused on treatment.</div></div><div><h3>Methods</h3><div>A systematic literature review was conducted covering the period from October 2020 to October 2025.</div></div><div><h3>Results</h3><div>L-6 and JAK inhibitors (JAKi) show efficacy comparable to rituximab (RTX) and abatacept (ABA) in controlling joint disease, preserving pulmonary function, limiting radiological progression, and reducing RA-ILD-related mortality, without a significant increase in serious respiratory events. ABA has not demonstrated a lower risk of severe or opportunistic infections; therefore, these four options (ABA, RTX, anti-IL6, and JAKi) may be used interchangeably in RA-ILD patients requiring treatment intensification. In those with a progressive fibrosing phenotype and intolerance to nintedanib, pirfenidone may be considered.</div></div><div><h3>Conclusions</h3><div>Recent evidence has expanded the therapeutic options available for RA-ILD.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 4","pages":"Article 502104"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147679938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoinflammatory syndromes in adults: report of 8 cases","authors":"Nuria Garvín Grande ,&nbsp;Paloma Turiel Hernández ,&nbsp;Manuel Beladiez Giner ,&nbsp;Giancarlo Ernesto Candela Ganoza ,&nbsp;Nicolás Silvestre Torner ,&nbsp;Paz Collado Ramos","doi":"10.1016/j.reumae.2026.502126","DOIUrl":"10.1016/j.reumae.2026.502126","url":null,"abstract":"<div><h3>Introduction</h3><div>Retrospective study documenting the clinical features, demographic and analytical parameters and therapeutic management in a cohort of adult patients with AIS.</div></div><div><h3>Clinical description</h3><div>Eight patients (50% male) were included, the majority of whom were Caucasian. The most frequent AIS was AOSD (37,5%). The mean age at symptom onset was 40 ± 23,1 years. The mean diagnostic delay was 5,7 ± 5 years. Fever, skin rash and myalgias were the most prevalent symptoms. The mean CRP value was 187,1 ± 110 mg/L and ESR rate of 95,2 ± 38 mm/h. 100% were treated with systemic corticosteroids, 50% with int i-IL-1. 3 patients required a switch from anakinra to canakinumab due to intolerance or lack of efficacy.</div></div><div><h3>Conclusions</h3><div>Given its increasing prevalence, this study emphasizes the importance of not underestimating the existence of AIS in adults, regardless of the level of health care. Early diagnosis and treatment with i-IL-1 are essential to control disease activity and prevent serious complications.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 4","pages":"Article 502126"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147679786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous and serological profiles of idiopathic inflammatory myopathies in a hispanic population","authors":"Selene Maribel Delgado-Ayala ,&nbsp;Sonia Chávez-Álvarez ,&nbsp;Jorge Ocampo-Candiani ,&nbsp;Miguel Ángel Villarreal-Alarcón ,&nbsp;Dionicio Ángel Galarza-Delgado ,&nbsp;Lourdes Gil-Flores ,&nbsp;David Vega-Morales","doi":"10.1016/j.reumae.2026.502100","DOIUrl":"10.1016/j.reumae.2026.502100","url":null,"abstract":"<div><h3>Introduction</h3><div>In the diagnosis and management of idiopathic inflammatory myopathies, cutaneous manifestations are particularly significant. Clinical signs are often associated with specific autoantibodies and play a role in the classification, treatment, and prognosis of IIM.</div></div><div><h3>Objective</h3><div>Describe the cutaneous clinical presentation, phototype, and autoantibody profiles among Hispanic patients with IIM.</div></div><div><h3>Methods</h3><div>A cross-sectional study was conducted from January 2015 to November 2022, including 64 patients diagnosed with IIM. Rheumatological and dermatological evaluations were performed, assessing Fitzpatrick phototype and Cutaneous Dermatomyositis Activity and Severity Index (CDASI) scores. Autoantibodies were analyzed using immunoblotting.</div></div><div><h3>Results</h3><div>Dermatomyositis (DM) was the most common subtype (73.4%). Fitzpatrick phototypes IV (59.4%) and III (37.5%) predominated. CDASI scores indicated mild dermatological activity in 60.9% of cases. Cluster analysis identified four patient groups with distinct clinical and serological profiles.</div></div><div><h3>Conclusion</h3><div>IIM have a complex disease expression. Recognizing its heterogeneities can enhance personalized treatment approaches.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 3","pages":"Article 502100"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147617293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minor salivary gland biopsy: A less invasive technique and applications","authors":"Mónica Fernández-Castro ,&nbsp;Carolina Merino ,&nbsp;Natalia de la Torre ,&nbsp;Pablo Navarro ,&nbsp;María Machattou ,&nbsp;María Concepción Sánchez-Fernández ,&nbsp;Andrea Liso ,&nbsp;Martín Luz Martín-Fragueiro ,&nbsp;José Luis Rodríguez Carrillo ,&nbsp;Jose Luis Andreu ,&nbsp;Jesús Sanz","doi":"10.1016/j.reumae.2026.502077","DOIUrl":"10.1016/j.reumae.2026.502077","url":null,"abstract":"<div><div>Minor salivary gland biopsy (MSGB) plays a pivotal role in the classification and diagnosis of Sjögren’s disease, one of the most prevalent systemic autoimmune disorders within the spectrum of rheumatic diseases. Furthermore, it provides valuable phenotypic information about the patient, contributes to the assessment of disease prognosis, and serves as a reliable tool for monitoring therapeutic response. MSGB is also useful in the diagnosis of amyloidosis, sarcoidosis, IgG4 disease, or lymphoma. In recent years, less invasive techniques have become increasingly widespread and have been proposed as highly accessible procedures for rheumatologists—straightforward to perform and associated with minimal or no complications. Consequently, MSGB has become a key diagnostic and follow-up tool in the comprehensive management of the disease.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 3","pages":"Article 502077"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147489080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}